Clarivate（CLVT）株式概要
米州、中東、アフリカ、欧州、アジア太平洋地域で情報サービスを提供。 詳細
CLVT Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$4.21
FV
41.6% 割安 内在価値ディスカウント58
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Clarivate Plc 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$2.46 |
| 52週高値 | US$4.77 |
| 52週安値 | US$1.66 |
| ベータ | 1.41 |
| 1ヶ月の変化 | -10.22% |
| 3ヶ月変化 | 38.20% |
| 1年変化 | -41.29% |
| 3年間の変化 | -67.42% |
| 5年間の変化 | -91.66% |
| IPOからの変化 | -81.75% |
最新ニュース
Seeking Alpha • May 13
Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough
Summary Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified. I maintain a hold rating, seeking several more quarters of cleaner execution and stronger IPPG performance before turning more constructive. Read the full article on Seeking Alpha
ナラティブの更新 • May 06
CLVT: Life Sciences Sale Execution Will Drive Upside Despite AI Risk
Analysts have trimmed their price expectations for Clarivate, with new targets ranging roughly from $2.40 to $6.00. They cited concerns around AI-related disruption risks and execution on the planned Life Sciences and Healthcare asset sale.Recent updates
Seeking Alpha • May 13
Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough
Summary Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified. I maintain a hold rating, seeking several more quarters of cleaner execution and stronger IPPG performance before turning more constructive. Read the full article on Seeking Alphaナラティブの更新 • May 06
CLVT: Life Sciences Sale Execution Will Drive Upside Despite AI Risk
Analysts have trimmed their price expectations for Clarivate, with new targets ranging roughly from $2.40 to $6.00. They cited concerns around AI-related disruption risks and execution on the planned Life Sciences and Healthcare asset sale.
ナラティブの更新 • Apr 21
CLVT: Free Cash Flow And Portfolio Simplification May Support Future Upside Potential
The Analyst Price Target for Clarivate has been reduced by about $1, with analysts pointing to AI disintermediation risk and uncertainty around the planned Life Sciences and Healthcare unit sale as key reasons for the reset. Analyst Commentary Recent research points to a more cautious stance on Clarivate, with several banks trimming price targets while keeping a range of ratings from Underweight to Buy.
ナラティブの更新 • Apr 07
CLVT: Fair Value View Weighs AI Disruption Against Portfolio Reshaping Risks
Analyst price targets on Clarivate have reset sharply lower into a $2.40 to $6 range, with cuts of up to about $2 to $2.60 as analysts factor in AI disruption risks and uncertainty around the planned Life Sciences and Healthcare segment sale. Analyst Commentary Recent research updates on Clarivate highlight a cautious tilt, with several bearish analysts resetting expectations lower despite references to solid free cash flow metrics and outlined growth targets.ナラティブの更新 • Mar 24
CLVT: Fair Value View Balances AI Competition With Portfolio Execution Risks
Clarivate's analyst price targets have moved lower toward a new implied fair value near $2.40 per share, as analysts factor in slower revenue growth assumptions, lower profit margin expectations, AI related competitive risks, and execution risk around the planned Life Sciences and Healthcare unit sale. Analyst Commentary Recent Street research on Clarivate has tilted more cautious, with several bearish analysts cutting price targets and, in one case, downgrading the stock.ナラティブの更新 • Mar 10
CLVT: Value Creation Plan Execution Will Drive Upside Despite AI Headwinds
Our analyst price target for Clarivate has moved down from $7.00 to $6.00 as analysts trim their targets across the Street. They cite AI related competitive pressures, the execution risk around a potential Life Sciences and Healthcare sale, and a longer timeline for the company’s Value Creation Plan to play out.ナラティブの更新 • Feb 24
CLVT: Extended Plan Execution Will Unlock Value Despite Rising AI Competition
Analysts have trimmed their $4.20 price target on Clarivate to $3.60, reflecting concerns that rising competition from AI-focused rivals, limits on pricing power, and a longer timeline for the company's "Value Creation Plan" temper expectations for organic revenue growth and profitability. Analyst Commentary Goldman Sachs cut its rating on Clarivate to Neutral from Buy and reduced its price target to $3.60 from $4.20, signaling a more cautious stance on the shares.ナラティブの更新 • Feb 09
CLVT: Extended Value Creation Plan Timeline May Support Future Upside Potential
Analysts have trimmed their price target on Clarivate to about US$3.60 from roughly US$4.20, citing a longer timeline for the company's "Value Creation Plan" to influence organic revenue growth, as well as concerns about pressure from AI driven competitors and limited pricing power. Analyst Commentary Bullish Takeaways Bullish analysts still see some value support around the revised US$3.60 target, suggesting expectations have been reset to reflect slower organic growth execution.分析記事 • Feb 04
Clarivate Plc's (NYSE:CLVT) 35% Dip In Price Shows Sentiment Is Matching Revenues
Clarivate Plc ( NYSE:CLVT ) shareholders that were waiting for something to happen have been dealt a blow with a 35...ナラティブの更新 • Jan 25
CLVT: Extended Plan And AI Competition Will Shape Long-Term Execution Outlook
Analysts have trimmed their price target on Clarivate to $3.60 from $4.20, citing expectations for a longer timeline for the Value Creation Plan to influence organic revenue growth, as well as concerns around competition from AI focused peers and limited pricing power. Analyst Commentary Recent Street research reflects a more cautious stance on Clarivate, with at least one major firm reducing its rating and target price as expectations temper around execution of the Value Creation Plan and the pace of organic revenue growth.ナラティブの更新 • Jan 09
CLVT: Extended Value Creation Timeline Will Confront Intensifying AI Competition
Analysts have trimmed their fair value estimate for Clarivate from US$3.75 to US$3.00, citing a lower Street price target and expectations that the company’s "Value Creation Plan" and efforts to improve organic revenue growth may take longer to show results in the face of rising AI driven competition and limited pricing power. Analyst Commentary Recent Street commentary has turned more cautious on Clarivate, with some price targets cut and ratings pulled back as expectations around the "Value Creation Plan" are reset to a longer timetable.ナラティブの更新 • Dec 22
CLVT: Share Repurchases Will Support Future Earnings Upside
Analysts have trimmed their price target on Clarivate by approximately $0.25. This reflects slightly higher perceived risk via a modestly increased discount rate and a lower future earnings multiple, while leaving their long term growth and profitability assumptions essentially unchanged.ナラティブの更新 • Dec 08
CLVT: Share Buybacks And Raised Guidance Will Support Future Performance
Analysts have slightly lowered their price target on Clarivate to reflect modestly reduced discount rate assumptions and a marginally lower future price-to-earnings multiple, while keeping their fair value estimate effectively unchanged at approximately $4.93 per share. What's in the News Clarivate completed a share repurchase of 34,823,885 shares, representing 5.11% of outstanding shares, for a total of $149.47 million under its December 16, 2024 buyback authorization (Key Developments).ナラティブの更新 • Nov 24
CLVT: Strong Market Share Will Support Future Performance Despite AI Risk
Analysts have slightly raised their price target for Clarivate to nearly $5 per share. They cite the firm’s solid market position but note ongoing risks from budget constraints, AI competition, and leverage concerns.ナラティブの更新 • Nov 09
CLVT: Market Position And AI Developments Will Drive Performance Ahead
Analysts have lowered Clarivate's price target from approximately $5.14 to $4.93 per share. They cite concerns over budget constraints in key sectors, potential risks from artificial intelligence, and the company’s elevated leverage, despite its strong market position.分析記事 • Sep 16
These 4 Measures Indicate That Clarivate (NYSE:CLVT) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Aug 02
Earnings Update: Clarivate Plc (NYSE:CLVT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
One of the biggest stories of last week was how Clarivate Plc ( NYSE:CLVT ) shares plunged 20% in the week since its...分析記事 • Jul 26
Is There An Opportunity With Clarivate Plc's (NYSE:CLVT) 32% Undervaluation?
Key Insights Clarivate's estimated fair value is US$6.63 based on 2 Stage Free Cash Flow to Equity Clarivate's US$4.53...分析記事 • Jul 08
At US$4.40, Is Clarivate Plc (NYSE:CLVT) Worth Looking At Closely?
While Clarivate Plc ( NYSE:CLVT ) might not have the largest market cap around , it led the NYSE gainers with a...新しいナラティブ • May 11
Subscription Model And AI Integration Will Drive Operational Efficiency
Transitioning to a subscription-based model and AI innovation enhances revenue stability and competitive edge, supporting growth and improving net margins.分析記事 • May 04
Optimistic Investors Push Clarivate Plc (NYSE:CLVT) Shares Up 27% But Growth Is Lacking
Clarivate Plc ( NYSE:CLVT ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...分析記事 • Apr 23
Clarivate Plc (NYSE:CLVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Key Insights Clarivate's estimated fair value is US$4.92 based on 2 Stage Free Cash Flow to Equity Current share price...分析記事 • Apr 08
Should You Investigate Clarivate Plc (NYSE:CLVT) At US$3.37?
Clarivate Plc ( NYSE:CLVT ), is not the largest company out there, but it saw significant share price movement during...分析記事 • Mar 03
Some Confidence Is Lacking In Clarivate Plc's (NYSE:CLVT) P/S
It's not a stretch to say that Clarivate Plc's ( NYSE:CLVT ) price-to-sales (or "P/S") ratio of 1.2x right now seems...Seeking Alpha • Feb 23
Clarivate: Another Weak Year Ahead
Summary I recommend maintaining a hold rating on Clarivate Plc due to poor organic growth prospects and declining EBITDA despite cost-cutting measures. FY25 is expected to be another challenging year with no signs of organic growth recovery and continued demand weakness across key segments. High debt levels and declining free cash flow raise concerns about CLVT's ability to manage its balance sheet and refinance upcoming debt. While management's strategic asset sales may benefit long-term revenue predictability, they will negatively impact near-term revenue and EBITDA. Read the full article on Seeking Alpha分析記事 • Jan 26
Is Clarivate (NYSE:CLVT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 08
Are Investors Undervaluing Clarivate Plc (NYSE:CLVT) By 27%?
Key Insights The projected fair value for Clarivate is US$7.07 based on 2 Stage Free Cash Flow to Equity Clarivate is...Seeking Alpha • Dec 26
Clarivate: Clearing The Decks
Summary Clarivate Plc's shares have rebounded somewhat after hitting an all-time low following weak 3Q24 results under new CEO Matti Shem Tov, who will reveal a Value Creation Plan in February. The company faces challenges with declining revenues and high debt, leading to mixed analyst ratings and a cautious outlook until more details of the turnaround plan are revealed. The stock is cheap on a P/E basis, and there was significant insider buying in November from beneficial owners. An analysis around Clarivate plc. follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Dec 16
Is Clarivate Plc (NYSE:CLVT) Potentially Undervalued?
Clarivate Plc ( NYSE:CLVT ), is not the largest company out there, but it saw a double-digit share price rise of over...Seeking Alpha • Nov 08
Clarivate: Downgrade To Hold As Growth May Take A Long Time To Recover
Summary I downgrade Clarivate PLC from buy to hold due to lack of confidence in near-term organic growth recovery and potential further stock price decline. CLVT's 3Q24 earnings report showed a 3.9% revenue decline and worsening organic growth, marking the worst performance in its history. The new CEO's Value Creation Plan is promising but will take a long time to show results, adding to the uncertainty. External headwinds in A&G and LS&G segments further dampen growth prospects, making it prudent to avoid investing until the outlook improves. Read the full article on Seeking Alpha分析記事 • Nov 07
Some Confidence Is Lacking In Clarivate Plc (NYSE:CLVT) As Shares Slide 26%
Clarivate Plc ( NYSE:CLVT ) shares have had a horrible month, losing 26% after a relatively good period beforehand. The...分析記事 • Sep 27
Here's Why Clarivate (NYSE:CLVT) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Sep 06
Clarivate Plc (NYSE:CLVT) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Clarivate Plc ( NYSE:CLVT ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • Aug 29
Is Clarivate Plc (NYSE:CLVT) Trading At A 43% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Clarivate fair value estimate is US$11.73 Clarivate is...Seeking Alpha • Aug 09
Clarivate: Attractive Upside Even With Conservative Assumptions
Summary A buy rating is recommended for Clarivate due to the expected organic growth improvement. Recent earnings showed a revenue decline, but organic growth showed a positive recovery, particularly in the A&G and IP segments. Valuation is cheap at 6.5x forward PE, with potential for multiple expansions as growth accelerates. Read the full article on Seeking Alpha株主還元
| CLVT | US Professional Services | US 市場 | |
|---|---|---|---|
| 7D | 0.8% | 4.3% | -0.3% |
| 1Y | -41.3% | -24.3% | 26.7% |
業界別リターン: CLVT過去 1 年間で-24.3 % の収益を上げたUS Professional Services業界を下回りました。
リターン対市場: CLVTは、過去 1 年間で26.7 % のリターンを上げたUS市場を下回りました。
価格変動
| CLVT volatility | |
|---|---|
| CLVT Average Weekly Movement | 14.4% |
| Professional Services Industry Average Movement | 7.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CLVTの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CLVTの 週次ボラティリティ は、過去 1 年間で9%から14%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1864 | 12,000 | Matti Shem Tov | www.clarivate.com |
米州、中東、アフリカ、欧州、アジア太平洋地域で情報サービスを提供。事業セグメントは3つ：アカデミア＆政府、知的財産、ライフサイエンス＆ヘルスケア。同社は、科学・学術研究ソリューション、AIネイティブソリューションのWeb of Science Research Intelligence、データベース、学位論文、ニュース、一次資料、書籍、ビデオフォーマットなどの学際的なキュレーションコンテンツにアクセスするためのProQuestソリューション、図書館サービスプラットフォームのAlmaを含む図書館ソフトウェア、公共図書館向けのVegaとPolarisを提供している。また、特許の維持・管理サービス、AIを活用した検索「ダーウェント・イノベーション」、特許公報の関連概念を特定し、新しい技術や馴染みのない技術のカテゴリーをナビゲートする「ダーウェント・ワールド・パテント・インデックス」、商標検索・監視ソリューション「コンピュマーク」、マネージドサービス「IP Recordals」、AIを活用した商標リスク評価・論証作成支援ツール「RiskMark」なども提供している。さらに、管理プラットフォームIPfolio、法律事務所向けFoundationIPソリューション、市場評価、競合他社分析、規制遵守、医薬品安全性に関する意思決定用Cortellis、Regulatory Intelligenceプラットフォーム、商業ソリューション、Medtechソリューションを提供している。学術機関、政府機関、ライフサイエンス、製薬会社にサービスを提供している。以前はClarivate Analytics Plcとして知られ、2020年5月にClarivate Plcに社名変更した。クラリベイトPlcは1864年に設立され、英国ロンドンに本社を置いている。
Clarivate Plc 基礎のまとめ
| CLVT 基礎統計学 | |
|---|---|
| 時価総額 | US$1.59b |
| 収益（TTM） | -US$137.40m |
| 売上高(TTM) | US$2.45b |
0.6x
P/Sレシオ-11.4x
PER（株価収益率CLVT は割高か？
公正価値と評価分析を参照収益と収入
| CLVT 損益計算書（TTM） | |
|---|---|
| 収益 | US$2.45b |
| 売上原価 | US$818.70m |
| 売上総利益 | US$1.63b |
| その他の費用 | US$1.77b |
| 収益 | -US$137.40m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.21 |
| グロス・マージン | 66.54% |
| 純利益率 | -5.62% |
| 有利子負債／自己資本比率 | 88.9% |
CLVT の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/20 07:21 |
| 終値 | 2026/05/20 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Clarivate Plc 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Manav Patnaik | Barclays |
| Heather Balsky | BofA Global Research |
| Zachary Cummins | B. Riley Securities, Inc. |